Pfizer Inc Stock Current Valuation
| PFE Stock | EUR 24.57 0.13 0.53% |
Valuation analysis of Pfizer Inc helps investors to measure Pfizer's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Pfizer's price fluctuation is very steady at this time. Calculation of the real value of Pfizer Inc is based on 3 months time horizon. Increasing Pfizer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pfizer stock is determined by what a typical buyer is willing to pay for full or partial control of Pfizer Inc. Since Pfizer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pfizer Stock. However, Pfizer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.57 | Real 21.7 | Hype 24.57 | Naive 25.65 |
The real value of Pfizer Stock, also known as its intrinsic value, is the underlying worth of Pfizer Inc Company, which is reflected in its stock price. It is based on Pfizer's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pfizer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pfizer Inc helps investors to forecast how Pfizer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pfizer more accurately as focusing exclusively on Pfizer's fundamentals will not take into account other important factors: Pfizer Inc Company Current Valuation Analysis
Pfizer's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pfizer Current Valuation | 276.06 B |
Most of Pfizer's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pfizer Inc has a Current Valuation of 276.06 B. This is much higher than that of the Healthcare sector and 51.79% higher than that of the Drug Manufacturers - Major industry. The current valuation for all Germany stocks is significantly lower than that of the firm.
Pfizer Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in current valuation category among its peers.
Pfizer Fundamentals
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 276.06 B | |||
| Shares Outstanding | 5.62 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 71.00 % | |||
| Price To Earning | 16.17 X | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 2.85 X | |||
| Revenue | 100.33 B | |||
| Gross Profit | 66.23 B | |||
| EBITDA | 39.58 B | |||
| Net Income | 31.37 B | |||
| Cash And Equivalents | 11.7 B | |||
| Cash Per Share | 2.10 X | |||
| Total Debt | 34.76 B | |||
| Debt To Equity | 78.80 % | |||
| Current Ratio | 1.54 X | |||
| Book Value Per Share | 17.03 X | |||
| Cash Flow From Operations | 32.58 B | |||
| Earnings Per Share | 5.16 X | |||
| Price To Earnings To Growth | 1.19 X | |||
| Number Of Employees | 83 K | |||
| Beta | 0.58 | |||
| Market Capitalization | 212.98 B | |||
| Total Asset | 181.48 B | |||
| Z Score | 3.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.17 % | |||
| Net Asset | 181.48 B | |||
| Last Dividend Paid | 1.6 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.